International Aids Vaccine
Initiative Inc.
Dba International Aids Vaccine
Initiative Inc
CAGE Code: 44YM6
NCAGE Code: 44YM6
Status: Active
Type: Commercial Supplier
Dun & Bradstreet (DUNS): 020790895
Summary
International Aids Vaccine, Initiative Inc., Dba International Aids Vaccine, Initiative Inc is an Active Commercial Supplier with the Cage Code 44YM6 and is tracked by Dun & Bradstreet under DUNS Number 020790895..
Address
125 Broad St Fl 9
New York NY 10004-2743
United States
Points of Contact
Related Information
People who viewed this 'CAGE Code' also viewed...
Tempo Sense Inc Trumeter Co Inc Doctors Without Borders Lorrillard Tobacco Co Industrial Scientific Co Amerotron Corp Fuller George A Co Div Of Northrop Standard Industries Inc M Rosenblatt & Son Inc American Business Machines Inc Associated American Trading Div Of Syrkus And Guttman Inc Rhi Entertainment Inc A B C Inc Play Co Toys Inc Buttling Padgett Co Inc Mutual Electric And Machine Corp Vulcan Machine And Mfg Inc Anchor Steel Co National Ignition Mfg Co Inc
Frequently Asked Questions (FAQ) for CAGE 44YM6
- What is CAGE Code 44YM6?
- 44YM6 is the unique identifier used by NATO Organizations to reference the physical entity known as International Aids Vaccine Initiative Inc. Dba International Aids Vaccine Initiative Inc located at 125 Broad St Fl 9, New York NY 10004-2743, United States.
- Who is CAGE Code 44YM6?
- 44YM6 refers to International Aids Vaccine Initiative Inc. Dba International Aids Vaccine Initiative Inc located at 125 Broad St Fl 9, New York NY 10004-2743, United States.
- Where is CAGE Code 44YM6 Located?
- CAGE Code 44YM6 is located in New York, NY, USA.
Contracting History for CAGE 44YM6 Most Recent 25 Records
- 75N93023F00001
- Contract Hhsn272201800010i International Aids Vaccine Initiative Manufacture Of Influenza Virus Human Challenge Material For Phase I And Ii Clinical Testing
- 26 Sep 2023
- Contract Hhsn272201800010i International Aids Vaccine Initiative Manufacture Of Influenza Virus Human Challenge Material For Phase I And Ii Clinical Testing
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,494,007.00
- Department Of Health And Human Services (Hhs)
- 75N93023F00001
- Contract Hhsn272201800010i International Aids Vaccine Initiative; Manufacture Of Influenza Virus Human Challenge Material For Phase I And Ii Clinical Testing
- 11 Dec 2023
- Contract Hhsn272201800010i International Aids Vaccine Initiative; Manufacture Of Influenza Virus Human Challenge Material For Phase I And Ii Clinical Testing
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $3,555,386.00
- Department Of Health And Human Services (Hhs)
- 75N93023D00010
- Preclinical Services For Biopharmaceutical Product Development: Base Idiq
- 8 Sep 2023
- Preclinical Services For Biopharmaceutical Product Development: Base Idiq
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $0.00
- Department Of Health And Human Services (Hhs)
- 75N93021F00240
- Coordination And Technical Support
- 27 Feb 2023
- Coordination And Technical Support
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $358,683.00
- Department Of Health And Human Services (Hhs)
- 75N93021F00240
- Coordination And Technical Support
- 6 Jun 2022
- Coordination And Technical Support
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $358,683.00
- Department Of Health And Human Services (Hhs)
- 75N93021F00240
- Coordination And Technical Support
- 7 Jul 2021
- Coordination And Technical Support
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $178,164.00
- Department Of Health And Human Services (Hhs)
- 75N93021F00239
- This Task Order Is To Develop An Optimized Phase 1 Cgmp Manufacturing Process For Lipid Nanoparticle (Lnp) Fabrication That Enable Covalent Coupling Of An Hiv-1 Env Trimer To The Surface Of The Lnp. A Non-Gmp Process Run Of Drug Product Shall Be Perf
- 28 Feb 2022
- This Task Order Is To Develop An Optimized Phase 1 Cgmp Manufacturing Process For Lipid Nanoparticle (Lnp) Fabrication That Enable Covalent Coupling Of An Hiv-1 Env Trimer To The Surface Of The Lnp. A Non-Gmp Process Run Of Drug Product Shall Be Perf
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,615,732.00
- Department Of Health And Human Services (Hhs)
- 75N93021F00239
- This Task Order Is To Develop An Optimized Phase 1 Cgmp Manufacturing Process For Lipid Nanoparticle (Lnp) Fabrication That Enable Covalent Coupling Of An Hiv-1 Env Trimer To The Surface Of The Lnp. A Non-Gmp Process Run Of Drug Product Shall Be Perf
- 13 Sep 2023
- This Task Order Is To Develop An Optimized Phase 1 Cgmp Manufacturing Process For Lipid Nanoparticle (Lnp) Fabrication That Enable Covalent Coupling Of An Hiv-1 Env Trimer To The Surface Of The Lnp. A Non-Gmp Process Run Of Drug Product Shall Be Perf
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $2,250,744.00
- Department Of Health And Human Services (Hhs)
- 75N93021F00239
- This Task Order Is To Develop An Optimized Phase 1 Cgmp Manufacturing Process For Lipid Nanoparticle (Lnp) Fabrication That Enable Covalent Coupling Of An Hiv-1 Env Trimer To The Surface Of The Lnp. A Non-Gmp Process Run Of Drug Product Shall Be Perf
- 7 Jun 2023
- This Task Order Is To Develop An Optimized Phase 1 Cgmp Manufacturing Process For Lipid Nanoparticle (Lnp) Fabrication That Enable Covalent Coupling Of An Hiv-1 Env Trimer To The Surface Of The Lnp. A Non-Gmp Process Run Of Drug Product Shall Be Perf
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,868,692.00
- Department Of Health And Human Services (Hhs)
- 75N93021F00239
- This Task Order Is To Develop An Optimized Phase 1 Cgmp Manufacturing Process For Lipid Nanoparticle (Lnp) Fabrication That Enable Covalent Coupling Of An Hiv-1 Env Trimer To The Surface Of The Lnp. A Non-Gmp Process Run Of Drug Product Shall Be Perf
- 2 Dec 2021
- This Task Order Is To Develop An Optimized Phase 1 Cgmp Manufacturing Process For Lipid Nanoparticle (Lnp) Fabrication That Enable Covalent Coupling Of An Hiv-1 Env Trimer To The Surface Of The Lnp. A Non-Gmp Process Run Of Drug Product Shall Be Perf
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,615,732.00
- Department Of Health And Human Services (Hhs)
- 75N93021F00239
- This Task Order Is To Develop An Optimized Phase 1 Cgmp Manufacturing Process For Lipid Nanoparticle (Lnp) Fabrication That Enable Covalent Coupling Of An Hiv-1 Env Trimer To The Surface Of The Lnp. A Non-Gmp Process Run Of Drug Product Shall Be Perf
- 31 Aug 2021
- This Task Order Is To Develop An Optimized Phase 1 Cgmp Manufacturing Process For Lipid Nanoparticle (Lnp) Fabrication That Enable Covalent Coupling Of An Hiv-1 Env Trimer To The Surface Of The Lnp. A Non-Gmp Process Run Of Drug Product Shall Be Perf
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,595,794.00
- Department Of Health And Human Services (Hhs)
- 75N93021F00001
- Hhsn272201800010i Iavi; Storage Of Gmp And Non-Gmp Materials For Niaid Base Award, Can 8470038 For $435,313.50; Can 8040917 For $435,313.50; Total $870,627
- 14 Sep 2021
- Hhsn272201800010i Iavi; Storage Of Gmp And Non-Gmp Materials For Niaid Base Award, Can 8470038 For $435,313.50; Can 8040917 For $435,313.50; Total $870,627
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $870,627.00
- Department Of Health And Human Services (Hhs)
- 75A50121C00077
- The Overall Objective Of This Contract Is To Advance The Development Of Monovalent Vaccines For Prevention Of Marburg Virus (Marv) And Sudan Ebolavirus (Sudv) Disease. These Vaccines Are Based On Recombinant Expression Of Filovirus Glycoproteins In
- 16 Apr 2022
- The Overall Objective Of This Contract Is To Advance The Development Of Monovalent Vaccines For Prevention Of Marburg Virus (Marv) And Sudan Ebolavirus (Sudv) Disease. These Vaccines Are Based On Recombinant Expression Of Filovirus Glycoproteins In
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $28,737,017.00
- Department Of Health And Human Services (Hhs)
- 75A50121C00077
- The Overall Objective Of This Contract Is To Advance The Development Of Monovalent Vaccines For Prevention Of Marburg Virus (Marv) And Sudan Ebolavirus (Sudv) Disease. These Vaccines Are Based On Recombinant Expression Of Filovirus Glycoproteins In
- 12 Sep 2022
- The Overall Objective Of This Contract Is To Advance The Development Of Monovalent Vaccines For Prevention Of Marburg Virus (Marv) And Sudan Ebolavirus (Sudv) Disease. These Vaccines Are Based On Recombinant Expression Of Filovirus Glycoproteins In
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $45,924,078.00
- Department Of Health And Human Services (Hhs)
- 75A50121C00077
- The Overall Objective Of This Contract Is To Advance The Development Of Monovalent Vaccines For Prevention Of Marburg Virus (Marv) And Sudan Ebolavirus (Sudv) Disease. These Vaccines Are Based On Recombinant Expression Of Filovirus Glycoproteins In
- 30 Sep 2021
- The Overall Objective Of This Contract Is To Advance The Development Of Monovalent Vaccines For Prevention Of Marburg Virus (Marv) And Sudan Ebolavirus (Sudv) Disease. These Vaccines Are Based On Recombinant Expression Of Filovirus Glycoproteins In
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $28,737,017.00
- Department Of Health And Human Services (Hhs)
- 75A50121C00077
- The Overall Objective Of This Contract Is To Advance The Development Of Monovalent Vaccines For Prevention Of Marburg Virus (Marv) And Sudan Ebolavirus (Sudv) Disease. These Vaccines Are Based On Recombinant Expression Of Filovirus Glycoproteins In
- 21 Jul 2023
- The Overall Objective Of This Contract Is To Advance The Development Of Monovalent Vaccines For Prevention Of Marburg Virus (Marv) And Sudan Ebolavirus (Sudv) Disease. These Vaccines Are Based On Recombinant Expression Of Filovirus Glycoproteins In
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $94,036,149.00
- Department Of Health And Human Services (Hhs)
- HDTRA121C0005
- Accelerated Vaccine Development Of A Saes-Cov-2 Vaccine Based On The Live Vsvag Chimeric Virus Platform
- 1 Dec 2022
- Accelerated Vaccine Development Of A Saes-Cov-2 Vaccine Based On The Live Vsvag Chimeric Virus Platform
- Defense Threat Reduction Agency
- Department Of Defense (Dod)
- $21,149,825.32
- Department Of Defense (Dod)
- HDTRA121C0005
- Accelerated Development Of A Sars-Cov-2 Vaccine Based On The Live Vsv.G Chimeric Virus Platform
- 16 Aug 2023
- Accelerated Development Of A Sars-Cov-2 Vaccine Based On The Live Vsv.G Chimeric Virus Platform
- Defense Threat Reduction Agency
- Department Of Defense (Dod)
- $25,301,003.61
- Department Of Defense (Dod)
- HDTRA121C0005
- Accelerated Development Of A Sars-Cov-2 Vaccine Based On The Live Vsvag Chimeric Virus Platform
- 5 Oct 2020
- Accelerated Development Of A Sars-Cov-2 Vaccine Based On The Live Vsvag Chimeric Virus Platform
- Defense Threat Reduction Agency
- Department Of Defense (Dod)
- $14,713,183.54
- Department Of Defense (Dod)
- HDTRA121C0005
- Accelerated Development Of A Sars-Cov-2 Vaccine Based On The Live Vsvag Chimeric Virus Platform
- 30 Jun 2021
- Accelerated Development Of A Sars-Cov-2 Vaccine Based On The Live Vsvag Chimeric Virus Platform
- Defense Threat Reduction Agency
- Department Of Defense (Dod)
- $14,713,183.54
- Department Of Defense (Dod)
- HDTRA121C0005
- Accelerated Development Of A Sars-Cov-2 Vaccine Based On The Live Vsvag Chimeric Virus Platform
- 25 May 2021
- Accelerated Development Of A Sars-Cov-2 Vaccine Based On The Live Vsvag Chimeric Virus Platform
- Defense Threat Reduction Agency
- Department Of Defense (Dod)
- $14,713,183.54
- Department Of Defense (Dod)
- HDTRA121C0005
- Accelerated Development Of A Sars-Cov-2 Vaccine Based On The Live Vsvag Chimeric Virus Platform
- 23 Dec 2020
- Accelerated Development Of A Sars-Cov-2 Vaccine Based On The Live Vsvag Chimeric Virus Platform
- Defense Threat Reduction Agency
- Department Of Defense (Dod)
- $14,713,183.54
- Department Of Defense (Dod)
- HDTRA121C0005
- Accelerated Development Of A Sars-Cov-2 Vaccine Based On The Live Vsvag Chimeric Virus Platform
- 23 Jul 2021
- Accelerated Development Of A Sars-Cov-2 Vaccine Based On The Live Vsvag Chimeric Virus Platform
- Defense Threat Reduction Agency
- Department Of Defense (Dod)
- $14,713,183.54
- Department Of Defense (Dod)
- HDTRA121C0005
- Accelerated Development Of A Sars-Cov-2 Vaccine Based On The Live Vsv.G Chimeric Virus Platform
- 4 May 2023
- Accelerated Development Of A Sars-Cov-2 Vaccine Based On The Live Vsv.G Chimeric Virus Platform
- Defense Threat Reduction Agency
- Department Of Defense (Dod)
- $24,301,003.61
- Department Of Defense (Dod)
- HDTRA121C0005
- Accelerated Development Of A Sars-Cov-2 Vaccine Based On The Live Vsvag Chimeric Virus Platform
- 7 Dec 2020
- Accelerated Development Of A Sars-Cov-2 Vaccine Based On The Live Vsvag Chimeric Virus Platform
- Defense Threat Reduction Agency
- Department Of Defense (Dod)
- $14,713,183.54
- Department Of Defense (Dod)